Pneumonia Therapeutics Market Overview:
The global pneumonia therapeutics market size was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030. Pneumonia therapeutics are used for prevention and treatment of patients suffering from pneumonia. Pneumonia is an infection that causes inflammation in individuals’ lungs, especially the alveoli. The alveoli gets filled up with fluid or pus. The symptoms in an individual affected with pneumonia include fever, chills, cough, and trouble in breathing. Furthermore, other common causes of viral pneumonia include respiratory syncytial virus (RSV), influenza, and SARS-CoV-2. In addition, commonly observed cause of bacterial pneumonia is Streptococcus pneumoniae (pneumococcus).
Surge in incidence of pneumonia is expected to propel the growth of the pneumonia therapeutics market during the forecast period. Furthermore, rise in prevalence of community-acquired pneumonia, especially in younger individuals is expected to fuel the growth of the market in the coming years. In addition, increase in prevalence demonstrates unmet clinical needs, which propels the demand for pneumonia therapeutics in the coming years. In addition, surge in R&D related to the treatment methods is expected to drive the market growth. However, lack of awareness regarding preventive vaccines is expected to hinder the growth of the market. On the contrary, surge in investments in the development of newer products that can be used as therapeutics for pneumonia is anticipated to create remunerative opportunities for the expansion of the pneumonia therapeutics market during the forecast period.
The World Health Organization on January 30, 2021 declared COVID-19 outbreak a public health emergency of international concern. Individual suffering COVID-19 is highly susceptible to pneumonia, thus causing shortness of breath and filling of mucus in the alveoli. This is expected to propel the growth of pneumonia therapeutics market. In addition, increase in R&D for the treatment of COVID-19-associated pneumonia is expected aid the market to generate high revenue during the forecast period. However, dearth of workforce as well as resource limitations due to COVID-19 are expected to negatively impact the growth of the industry in the forecast period. In addition, implementation of stringent government regulations regarding the lockdown has declined the market growth. Moreover, the need of the hour is to bring up newer products that can help combat with COVID-19. This helps the pneumonia therapeutics market to generate higher revenue during the forecast period.
Global Pneumonia Therapeutics Market Segmentation
The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is categorized into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment review
On the basis of therapeutics, the treatment drugs segment is expected to garner highest revenue during the forecast period, owing to rise in incidence of pneumonia. Furthermore, surge in demand for novel drugs among individuals suffering from pneumonia notably contributes toward the market growth. In addition, advent of resistant strains has boosted the need for R&D of vaccines, which is expected to help the segment generate higher revenue during the forecast period.
By Therapeutics
The Prevention Vaccines segment is expected to lead the market throughout the forecast period.
Depending on distribution channel, the hospitals segment is anticipated to dominate the market during the forecast period, owing to the availability of skilled professionals for the treatment of pneumonia and surge in number of outpatients and inpatients preferring hospitals. In addition, higher investment of hospitals for adopting novel pneumonia therapeutics methods for civil population is anticipated to propel the growth of hospital segment during the forecast period. Furthermore, rise in adoption of novel and efficient drugs for pneumonia treatment fosters the pneumonia therapeutics market growth.
By Distribution Channel
The Hospitals segment is expected to lead the market throughout the forecast period.
By age group, the geriatric segment led the global pneumonia therapeutics market in 2020, and is expected to continue this trend in the coming years. This is attributed to surge in geriatric population worldwide. Furthermore, susceptibility to develop age-associated diseases contributes toward the growth of the segment. However, the pediatric segment is expected to gain significant revenue shares, owing to the weaker immune system of the pediatric population and multidrug resistance observed.
By Region
North America segment held a highest revenue share in 2020, furthermore Asia-Pacific is expected to register the fastest CAGR during the forecast period.
The key players profiled in this report include Abbott Laboratories, Bayer AG, Eli Lilly & Company, Glaxosmithkline PLC., Lupin Pharmaceuticals, Inc., Merck KGAA, Novartis AG, Pfizer, Inc., Sanofi S.A., and Teva Pharmaceuticals Industries Limited.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the pneumonia therapeutics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- The report covers the pneumonia therapeutics market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of factors that drive and restrain the growth of the pneumonia therapeutics market is provided.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and pneumonia therapeutics market growth.
Key Market Segments
By Therapeutics
- Prevention Vaccines
- Treatment Drugs
By Distribution Channel
- Hospitals
- Pharmaceutical Stores
- Others
By Age Group
- Pediatric
- Adult
- Geriatric
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Pneumonia Therapeutics Market Report Highlights
| Aspects | Details |
 By THERAPEUTICS |
|
 By DISTRIBUTION CHANNEL |
|
 By AGE GROUP |
|
 By Region |
|
 Key Market Players | ELI LILLY & COMPANY, SANOFI S.A., PFIZER, INC., MERCK KGAA, BAYER AG, ABBOTT LABORATORIES, NOVARTIS AG, LUPIN PHARMACEUTICALS, INC., GlaxoSmithKline PLC, TEVA PHARMACEUTICALS INDUSTRIES LIMITED |
Analyst Review
Pneumonia therapeutics include both preventive methods and treatment medications such as vaccines and drugs. In addition, rise in prevalence of pneumonia of various types such as bacterial, viral, mycoplasma pneumonia would fuel the growth of the market in the coming years. Furthermore, the advent of unknown mutated microbes that are likely to cause pneumonia has boosted the need for research, and is expected to fuel the market growth during the forecast period. Rise in investment for development of medications to cure pneumonia is expected to propel the growth of the industry in the next few years. In addition, the advent of drug-resistant strains has opened newer avenues for the pneumonia therapeutics market.
North America is expected to gain significant shares in 2020, owing to surge in healthcare spending on respiratory diseases. Furthermore, surge in geriatric population and multidrug resistance among adults and children boost the need for novel drugs. This would help the region generate high revenue in the coming years. In addition, Asia-Pacific is anticipated to gain highest market share , owing to rise in the patient population and increase in the spending on the improvement of healthcare infrastructure.
Pneumonia therapeutics are those medications that are used to help manage with the pneumonia causing antigens.
Pneumonia therapeutics are used when the healthcare professionals require assistance in aiding the patients with medications or preventive measures for treating and preventing pneumonia.
The total value of pneumonia therapeutics market was $12,293.9 million in 2020.
The forecast period in the report is from 2021-2030.
The market value of pneumonia therapeutics market in 2030 was $25,546.8 million.
The base year calculated in the report is 2020.
Increased demand for the pneumonia therapeutics for assistance in prevention of pneumonia disease in the population will drive the market over the near future according to the KOLs.
The market has drawn the interest of the healthcare industry, owing to increasing prevalence of different types of pneumonia, rise in R&D in pneumonia therapeutics, and growing awareness among healthcare professionals regarding pneumonia therapeutics
By therapeutics, preventin vaccines segment holds the maximum market share.
The market in Asia-Pacific is expected to register lucrative CAGR of 10.0% and highest revenue over the forecast period owing to presence of large population base, increase in awareness regarding pneumonia therapeutics, and rise in disposable income
Loading Table Of Content...
